
Gyan Chandra
Examiner (ID: 12063, Phone: (571)272-2922 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1646, 1674 |
| Total Applications | 1424 |
| Issued Applications | 820 |
| Pending Applications | 137 |
| Abandoned Applications | 480 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20795420
[patent_doc_number] => 20260176319
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-06-25
[patent_title] => PEPTIDE ANALOGS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 19/415046
[patent_app_country] => US
[patent_app_date] => 2025-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40129
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19415046
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | Dec 9, 2025 | Pending |
Array
(
[id] => 20788615
[patent_doc_number] => 12662520
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-23
[patent_title] => Masked IL-2 cytokines and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 19/314420
[patent_app_country] => US
[patent_app_date] => 2025-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 35597
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19314420
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/314420 | Masked IL-2 cytokines and methods of use thereof | Aug 28, 2025 | Issued |
Array
(
[id] => 20362811
[patent_doc_number] => 20250352623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-20
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 19/281547
[patent_app_country] => US
[patent_app_date] => 2025-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19281547
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/281547 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | Jul 24, 2025 | Issued |
Array
(
[id] => 20670970
[patent_doc_number] => 12611465
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-28
[patent_title] => Protein-enclosing polymeric micelle
[patent_app_type] => utility
[patent_app_number] => 19/079771
[patent_app_country] => US
[patent_app_date] => 2025-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 8243
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19079771
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/079771 | Protein-enclosing polymeric micelle | Mar 13, 2025 | Issued |
Array
(
[id] => 20742969
[patent_doc_number] => 12642851
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-02
[patent_title] => Self-assembling nanoparticles
[patent_app_type] => utility
[patent_app_number] => 19/067426
[patent_app_country] => US
[patent_app_date] => 2025-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 50
[patent_no_of_words] => 94311
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19067426
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/067426 | Self-assembling nanoparticles | Feb 27, 2025 | Issued |
Array
(
[id] => 20864291
[patent_doc_number] => 12691162
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-07-28
[patent_title] => Multi-dose pen of tirzepatide
[patent_app_type] => utility
[patent_app_number] => 19/062335
[patent_app_country] => US
[patent_app_date] => 2025-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4082
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19062335
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/062335 | MULTI-DOSE PEN OF TIRZEPATIDE | Feb 24, 2025 | Issued |
Array
(
[id] => 20031861
[patent_doc_number] => 20250170083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY
[patent_app_type] => utility
[patent_app_number] => 19/041480
[patent_app_country] => US
[patent_app_date] => 2025-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19041480
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/041480 | Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy | Jan 29, 2025 | Issued |
Array
(
[id] => 19860763
[patent_doc_number] => 20250099549
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => GLP-1 RECEPTOR AGONISTS IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 18/979068
[patent_app_country] => US
[patent_app_date] => 2024-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18979068
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/979068 | Methods for treating Alzheimer's disease using semaglutide | Dec 11, 2024 | Issued |
Array
(
[id] => 20039267
[patent_doc_number] => 20250177489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 18/967259
[patent_app_country] => US
[patent_app_date] => 2024-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21698
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18967259
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/967259 | Compositions and methods for treating diabetes | Dec 2, 2024 | Issued |
Array
(
[id] => 20491539
[patent_doc_number] => 12533394
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Compositions and methods for treating metabolic disorders
[patent_app_type] => utility
[patent_app_number] => 18/929081
[patent_app_country] => US
[patent_app_date] => 2024-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 47
[patent_no_of_words] => 15567
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18929081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/929081 | Compositions and methods for treating metabolic disorders | Oct 27, 2024 | Issued |
Array
(
[id] => 19744024
[patent_doc_number] => 20250032589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => Insulin Derivative
[patent_app_type] => utility
[patent_app_number] => 18/889097
[patent_app_country] => US
[patent_app_date] => 2024-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18889097
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/889097 | Insulin Derivative | Sep 17, 2024 | Abandoned |
Array
(
[id] => 19931746
[patent_doc_number] => 12304943
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/807825
[patent_app_country] => US
[patent_app_date] => 2024-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 35
[patent_no_of_words] => 55563
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18807825
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/807825 | April and BAFF inhibitory immunomodulatory proteins and methods of use thereof | Aug 15, 2024 | Issued |
Array
(
[id] => 19360847
[patent_doc_number] => 20240262881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/634496
[patent_app_country] => US
[patent_app_date] => 2024-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 102214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634496
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/634496 | Fusion proteins for the treatment of cardiometabolic diseases | Apr 11, 2024 | Issued |
Array
(
[id] => 19777466
[patent_doc_number] => 12226487
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Therapeutic derivatives of interleukin-22
[patent_app_type] => utility
[patent_app_number] => 18/628440
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 26
[patent_no_of_words] => 20042
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628440
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/628440 | Therapeutic derivatives of interleukin-22 | Apr 4, 2024 | Issued |
Array
(
[id] => 19792188
[patent_doc_number] => 12233111
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-25
[patent_title] => Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/444463
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 55
[patent_no_of_words] => 76898
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444463
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/444463 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof | Feb 15, 2024 | Issued |
Array
(
[id] => 19216315
[patent_doc_number] => 20240181019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => USE OF ULTRARAPID ACTING INSULIN
[patent_app_type] => utility
[patent_app_number] => 18/440382
[patent_app_country] => US
[patent_app_date] => 2024-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440382
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/440382 | USE OF ULTRARAPID ACTING INSULIN | Feb 12, 2024 | Pending |
Array
(
[id] => 19318317
[patent_doc_number] => 20240239860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/430757
[patent_app_country] => US
[patent_app_date] => 2024-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14242
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430757
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/430757 | THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF | Feb 1, 2024 | Pending |
Array
(
[id] => 19140497
[patent_doc_number] => 20240139287
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => THERAPEUTIC USES OF DULAGLUTIDE
[patent_app_type] => utility
[patent_app_number] => 18/409277
[patent_app_country] => US
[patent_app_date] => 2024-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409277
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/409277 | THERAPEUTIC USES OF DULAGLUTIDE | Jan 9, 2024 | Pending |
Array
(
[id] => 19281863
[patent_doc_number] => 20240218337
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => FUSION PROTEIN TARGETING PD-L1 AND NEUTRALIZING GAS6 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/396245
[patent_app_country] => US
[patent_app_date] => 2023-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16377
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396245
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/396245 | FUSION PROTEIN TARGETING PD-L1 AND NEUTRALIZING GAS6 AND USES THEREOF | Dec 25, 2023 | Pending |
Array
(
[id] => 19233762
[patent_doc_number] => 20240190954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/510553
[patent_app_country] => US
[patent_app_date] => 2023-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510553
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/510553 | Antibody for binding to interleukin 4 receptor | Nov 14, 2023 | Issued |